HeartWare dives on big Q1 sales, earnings misses
Shares prices for HeartWare International (NSDQ:HTWR) plunged this morning after the implantable heart pump maker posted 1st-quarter earnings that badly missed expectations on Wall Street. Framingham, Mass.-based HeartWare reported that losses widened 20.1% to -$17.5 million, or -$1 per share, on a -21.3% revenue slide to $55.1 million. Adjusted to exclude 1-time items, losses per share were -95¢, -16¢ off the forecast on The Street, where analysts were looking for sales of $59.9 million. “In the 1st quarter, our international revenue performance was impacted by competitive dynamics in Germany, as well as lower implant volumes in certain other international markets,” president &CEO Doug Godshall said in prepared remarks. “In the U.S., the bridge-to-transplant segment of the market for which the HVAD system is approved, showed softness resulting from a slowdown in the volume of patients eligible for bridge-to-transplant procedures at the start of the year and an evolving trend toward destination therapy due to ease of reimbursement. Our 1st-quarter financial performance and the overall market dynamics reinforce the importance of our work toward securing a DT indication in the U.S. and focusing our energies upon the continued enhancement of our technologies. “Despite 1st-quarter trends, the HVAD system remains the most versatile pump, utilized in the widest range of patients, among currently available ventricular as...
This study is able to show uniform results that lie on a single side of the hemostatic scale (no thromboses, some bleeding). It is this type of result that can lead us to be conservative with anticoagulation. However, this trial is rare in the evolution of mechanical circulatory support (MCS) device management.
Ronald Reagan UCLA Medical Center led the nation in the number of solid organ transplants performed in 2017, with 641 procedures that included kidney, pancreas, lung, heart and intestine transplants, according to statistics from the Organ Procurement and Transplantation Network.UCLA recorded 363 kidney transplants in 2017, making it the year ’s top kidney transplant center.Other medical centers with a high number of solid organ transplants in 2017 were UC San Francisco; Jackson Memorial Hospital in Miami, Barnes-Jewish Hospital in St. Louis, Missouri; and the University of Wisconsin ’s University Hospital in Ma...
Emerging clinical evidence has suggested that short-term mechanical augmentation of cardiac output (CO) may not consistently improve mortality in patients with cardiogenic shock (CS), despite improvements in hemodynamics. Such failures could reflect the underlying complexity of the mechanisms that contribute to malperfusion and organ dysfunction in CS. Distinct molecular and physiologic shock endophenotypes likely exist among patients with CS, with hemodynamic aberrations as the inciting insult, but not necessarily the primary drivers of clinical outcomes.
Eighty five percent of congenital heart disease patients currently survive to adulthood due primarily to advancements in surgical treatments1. For these survivors with Adult Congenital Heart Disease (ACHD), heart failure (HF) remains the leading cause of death2. Thus, the number of ACHD patients requiring heart transplantation (HT) continues to grow, and with this growth has come improvements in outcomes. In 2009, Lamour et al. demonstrated a 1-year survival of 83% for non-Fontan congenital HT and 71% for patients with Fontan palliation3.
Treatment decisions in dilated cardiomyopathy (DCM) patients with severe heart failure (HF) and short clinical history are challenging because of the difficulty of determining HF stage or prognosis in the acute HF phase. We hypothesized that persistent decreased systemic or increased pulmonary arterial pressure, including in the subclinical phase, may affect the main pulmonary artery diameter (PAD), ascending aortic diameter (AoD), and their ratio (PAD/AoD). The aims of this study were to assess AoD, PAD, and PAD/AoD by non-contrast computed tomography (CT) scans in DCM patients in the acute phase of HF and to examine the ...
Nowadays, a number of heart failure (HF) patients live with left ventricular assist devices (LVADs) implanted either as a destination therapy or as a bridge to heart transplant or to heart transplant candidacy.1,2 In all these cases, LVAD usually remains for a prolonged time after post-surgical stabilization, during which patients ’ daily quality of life must be improved as much as possible. LVADs are usually set at a fixed number of revolutions per minute (rpm), so that LVAD output changes during daily activities are only preload- and afterload-dependent, with limited variability.
Sirolimus (SRL) attenuates cardiac allograft vasculopathy (CAV) progression following heart transplantation (HT) but often results in hyperlipidemia. We investigated the differential effects of SRL- and calcineurin inhibitor (CNI)-based immunosuppression on CAV progression and clinical outcomes in HT recipients.
: Venovenous (VV) extra corporeal membrane oxygenation (ECMO) is the preferred configuration for bridging respiratory failure patients while awaiting lung transplantation (LTx). However, there is no consensus about intraoperative extracorporeal cardiopulmonary support during LTx in these patients.
Aortic regurgitation (AR) developing under continuous flow-left ventricular assist devices (CF-LVAD) affects 25-30% of patients within the first year of implantation and is being increasingly recognized as a cause of recurrence of symptomatic heart failure (HF). The underlying mechanisms are likely multifactorial, including changes in the leaflets of the aortic valve (AV), altered root biomechanics and excessive left ventricular (LV) unloading, together promoting cusps remodeling and commissural fusion.
Registry data suggest that survival in pulmonary arterial hypertension (PAH) patients has improved from a median of 2.5 years from diagnosis to about 7 years in mostly prevalent cohorts,1,2 which is still dismal. There has long been a concern that initiation of therapy in PAH patients is insufficiently aggressive, given such poor survival. Until recently, data on the utility of combination therapy and the use of initial combination therapy in treatment-na ïve patients has been conflicting, uncontrolled, or nonexistent.